Cargando…
The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with molecular heterogeneity, inducing differences in biological behavior, and therapeutic strategy. NGS profiles of pathogenic alterations in the Chinese PDAC population are limited. We conducted a retrospective study to investi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273977/ https://www.ncbi.nlm.nih.gov/pubmed/34247626 http://dx.doi.org/10.1186/s12967-021-02972-6 |
_version_ | 1783721478086197248 |
---|---|
author | Shui, Lin Li, Xiaofen Peng, Yang Tian, Jiangfang Li, Shuangshuang He, Du Li, Ang Tian, Bole Li, Mao Gao, Heli An, Ning Yi, Cheng Cao, Dan |
author_facet | Shui, Lin Li, Xiaofen Peng, Yang Tian, Jiangfang Li, Shuangshuang He, Du Li, Ang Tian, Bole Li, Mao Gao, Heli An, Ning Yi, Cheng Cao, Dan |
author_sort | Shui, Lin |
collection | PubMed |
description | BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with molecular heterogeneity, inducing differences in biological behavior, and therapeutic strategy. NGS profiles of pathogenic alterations in the Chinese PDAC population are limited. We conducted a retrospective study to investigate the predictive role of DNA damage repair (DDR) mutations in precision medicine. METHODS: The NGS profiles were performed on resected tissues from 195 Chinese PDAC patients. Baseline clinical or genetic characteristics and survival status were collected. The Kaplan–Meier survival analyses were performed by the R version 3.6.1. RESULTS: The main driver genes were KRAS, TP53, CDKN2A, and SMAD4. Advanced patients with KRAS mutation showed a worse OS than KRAS wild-type (p = 0.048). DDR pathogenic deficiency was identified in 30 (15.38%) of overall patients, mainly involving BRCA2 (n = 9, 4.62%), ATM (n = 8, 4.10%) and RAD50 genes (n = 3, 1.54%). No significance of OS between patients with or without DDR mutations (p = 0.88). But DDR mutation was an independent prognostic factor for survival analysis of advanced PDAC patients (p = 0.032). For DDR mutant patients, treatment with platinum-based chemotherapy (p = 0.0096) or olaparib (p = 0.018) respectively improved the overall survival. No statistical difference between tumor mutation burden (TMB) and DDR mutations was identified. Treatment of PD-1 blockades did not bring significantly improved OS to DDR-mutated patients than the naive DDR group (p = 0.14). CONCLUSIONS: In this retrospective study, we showed the role of germline and somatic DDR mutation in predicting the efficacy of olaparib and platinum-based chemotherapy in Chinese patients. However, the value of DDR mutation in the prediction of hypermutation status and the sensitivity to the PD-1 blockade needed further investigation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02972-6. |
format | Online Article Text |
id | pubmed-8273977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82739772021-07-13 The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma Shui, Lin Li, Xiaofen Peng, Yang Tian, Jiangfang Li, Shuangshuang He, Du Li, Ang Tian, Bole Li, Mao Gao, Heli An, Ning Yi, Cheng Cao, Dan J Transl Med Research BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with molecular heterogeneity, inducing differences in biological behavior, and therapeutic strategy. NGS profiles of pathogenic alterations in the Chinese PDAC population are limited. We conducted a retrospective study to investigate the predictive role of DNA damage repair (DDR) mutations in precision medicine. METHODS: The NGS profiles were performed on resected tissues from 195 Chinese PDAC patients. Baseline clinical or genetic characteristics and survival status were collected. The Kaplan–Meier survival analyses were performed by the R version 3.6.1. RESULTS: The main driver genes were KRAS, TP53, CDKN2A, and SMAD4. Advanced patients with KRAS mutation showed a worse OS than KRAS wild-type (p = 0.048). DDR pathogenic deficiency was identified in 30 (15.38%) of overall patients, mainly involving BRCA2 (n = 9, 4.62%), ATM (n = 8, 4.10%) and RAD50 genes (n = 3, 1.54%). No significance of OS between patients with or without DDR mutations (p = 0.88). But DDR mutation was an independent prognostic factor for survival analysis of advanced PDAC patients (p = 0.032). For DDR mutant patients, treatment with platinum-based chemotherapy (p = 0.0096) or olaparib (p = 0.018) respectively improved the overall survival. No statistical difference between tumor mutation burden (TMB) and DDR mutations was identified. Treatment of PD-1 blockades did not bring significantly improved OS to DDR-mutated patients than the naive DDR group (p = 0.14). CONCLUSIONS: In this retrospective study, we showed the role of germline and somatic DDR mutation in predicting the efficacy of olaparib and platinum-based chemotherapy in Chinese patients. However, the value of DDR mutation in the prediction of hypermutation status and the sensitivity to the PD-1 blockade needed further investigation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02972-6. BioMed Central 2021-07-12 /pmc/articles/PMC8273977/ /pubmed/34247626 http://dx.doi.org/10.1186/s12967-021-02972-6 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Shui, Lin Li, Xiaofen Peng, Yang Tian, Jiangfang Li, Shuangshuang He, Du Li, Ang Tian, Bole Li, Mao Gao, Heli An, Ning Yi, Cheng Cao, Dan The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma |
title | The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma |
title_full | The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma |
title_fullStr | The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma |
title_full_unstemmed | The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma |
title_short | The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma |
title_sort | germline/somatic dna damage repair gene mutations modulate the therapeutic response in chinese patients with advanced pancreatic ductal adenocarcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273977/ https://www.ncbi.nlm.nih.gov/pubmed/34247626 http://dx.doi.org/10.1186/s12967-021-02972-6 |
work_keys_str_mv | AT shuilin thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT lixiaofen thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT pengyang thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT tianjiangfang thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT lishuangshuang thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT hedu thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT liang thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT tianbole thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT limao thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT gaoheli thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT anning thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT yicheng thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT caodan thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT shuilin germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT lixiaofen germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT pengyang germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT tianjiangfang germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT lishuangshuang germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT hedu germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT liang germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT tianbole germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT limao germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT gaoheli germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT anning germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT yicheng germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma AT caodan germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma |